Literature DB >> 17158761

Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.

Sin-Ming Chow1, Stephen Yau, Chung-Kong Kwan, Patricia C M Poon, Stephen C K Law.   

Abstract

To identify indications for external radiotherapy (EXT) and radioactive iodine (RAI) in papillary thyroid carcinoma (PTC), we conducted a retrospective study of local and regional control in 1297 patients diagnosed with PTC in a tertiary referral center. Managed by surgery alone, patients with bilateral thyroidectomy had a lower rate of local relapse compared with lobectomy (P=0.02). EXT improved locoregional (LR) failure-free survival (FFS) (P<0.001) and survival (P=0.01) in patients with gross postoperative LR residual disease. EXT also improved local FFS in patients with pathologically confirmed positive resection margins (P<0.001) and reduced local failures in patients with T4 disease (P=0.002). In patients with lymph nodes (LN) metastasis, more extensive surgery by functional or radical neck dissection resulted in less LN relapse compared with excision alone (P<0.001). EXT improved 10-year LN FFS in patients with N1b disease (P=0.005) and patients with LN metastasis of size>2 cm (P=0.02). RAI was effective in improving local control in patients with T2 to T4 diseases and LN control in patients with N0, N1a, and N1b categories. Local or LN relapses were associated with worse survival (P<0.001 and P<0.0001). The survival of patients with PTC could be improved by reducing local or LN relapses. RAI is indicated in patients with T2 to T4 disease. EXT is indicated in patients with gross postoperative disease, positive resection margins or T4 disease, N1b, or a LN size of >2 cm. LN relapse can be reduced by RAI in N0, N1a, and N1b disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158761     DOI: 10.1677/erc.1.01320

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  29 in total

1.  Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.

Authors:  Ewa Ruel; Samantha Thomas; Michaela Dinan; Jennifer M Perkins; Sanziana A Roman; Julie Ann Sosa
Journal:  J Clin Endocrinol Metab       Date:  2015-02-02       Impact factor: 5.958

2.  Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy.

Authors:  H Vulpe; J Y Y Kwan; A McNiven; J D Brierley; R Tsang; B Chan; D P Goldstein; L W Le; A Hope; M Giuliani
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

Review 3.  Management of Invasive Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Ricard Simo; Kate Newbold; Alessandra Rinaldo; Carlos Suarez; Luiz P Kowalski; Carl Silver; Jatin P Shah; Alfio Ferlito
Journal:  Thyroid       Date:  2016-08-23       Impact factor: 6.568

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.

Authors:  Samantha A Diamond-Rossi; Jacqueline Jonklaas; Roxanne E Jensen; Charlene Kuo; Selma Stearns; Giuseppe Esposito; Bruce J Davidson; George Luta; Gary Bloom; Kristi D Graves
Journal:  J Cancer Surviv       Date:  2020-06-06       Impact factor: 4.442

6.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

Review 7.  Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.

Authors:  Kenneth B Ain
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

8.  External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.

Authors:  Ana P Kiess; Nishant Agrawal; James D Brierley; Umamaheswar Duvvuri; Robert L Ferris; Eric Genden; Richard J Wong; R Michael Tuttle; Nancy Y Lee; Gregory W Randolph
Journal:  Head Neck       Date:  2015-12-30       Impact factor: 3.147

9.  Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure.

Authors:  Laura Y Wang; Ronald Ghossein; Frank L Palmer; Iain J Nixon; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Thyroid       Date:  2015-07-30       Impact factor: 6.568

10.  Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment.

Authors:  David L Schwartz; Mark J Lobo; K Kian Ang; William H Morrison; David I Rosenthal; Anesa Ahamad; Douglas B Evans; Gary Clayman; Steven I Sherman; Adam S Garden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-25       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.